Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma

Fig. 2

Survival Outcomes in RRMM Patients Treated with BCMA CAR-T Therapy. (A, B, C) Kaplan‒Meier survival curves illustrating the DOR, PFS, and OS for all 56 patients. (D) Accumulated best response rates after CAR-T-cell therapy. The red line indicates the progressive increase in the rates of CR or sCR over time. CR, complete response; DOR, duration of response; PFS, progression-free survival; PR, partial response; OS, overall survival; sCR, stringent complete response; VGPR, very good partial response

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us